Qiagen (QGEN) Upgraded to Buy by Deutsche Bank After 30% Decline

Qiagen N.V. (NYSE:QGEN) ranks among the oversold European stocks to buy. On March 13, Deutsche Bank upgraded Qiagen N.V. (NYSE:QGEN) to Buy from Hold, maintaining a $54 price target on the company’s shares. The firm stated that Qiagen’s stock had declined over 30% since late January’s M&A stories and accompanying downgrade, essentially pricing out any buyout premium.

According to the firm, the company’s 2026 outlook is back-end heavy, which is common among Diagnostics and Life Sciences competitors and is due in part to mechanical impacts reasonably reflected in current consensus estimates.

Qiagen N.V. (NYSE:QGEN) also outlined its strategy at the Barclays 28th Annual Global Healthcare Conference on March 10, emphasizing sustainable development objectives in the midst of a CEO transition.

Despite macroeconomic challenges and the temporary impact of discontinued products such as NeuMoDx, the company reiterated its 5% full-year growth estimate. Growth is likely to improve in the second half, boosted by the introduction of new sample-preparation products that could add up to 200 basis points to results.

Qiagen N.V. (NYSE:QGEN), based in the Netherlands, is a global leader in Sample-to-Insight solutions. The company provides technologies for extracting and analyzing DNA, RNA, and proteins from various samples.

While we acknowledge the risk and potential of QGEN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than QGEN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years. 

Disclosure: None. Follow Insider Monkey on Google News.